The ITA reports that weightlifter Dae Hee Kwon has agreed¹ to the consequences for his anti-doping rule violation (ADRV).
Dae Hee Kwon provided a sample under the testing authority of the IWF during an out-of-competition doping control performed on 26 February 2025, which yielded an adverse analytical finding² (AAF) for trimetazidine.
Trimetazidine is prohibited under the WADA Prohibited List as S4. Hormone and Metabolic Modulators. It is prohibited at all times (in- and out-of-competition) and is classified as a non-specified substance. Trimetazidine is a drug used inter alia to treat and prevent heart-related conditions by increasing blood flow to the heart.
When notified of the case, the athlete was provisionally suspended with immediate effect.³
The athlete did not challenge the ADRV and agreed with the consequences applicable as per the rules. Accordingly, the case was resolved via an acceptance of consequences.
Due to his early admission of the anti-doping rule violation, the athlete was entitled to a one-year reduction of the otherwise four-year period of ineligibility usually imposed for an ADRV for the presence of the prohibited substance as set forth in article 10.8.1 of the IWF anti-doping rules.⁴
The athlete’s period of ineligibility is from 14 April 2025 until 13 April 2028. In addition, all the athlete’s individual competitive results from 26 February 2025 to the start of the provisional suspension are disqualified.
The decision may be challenged before the appeals division of the Court of Arbitration for Sport by the parties with a right of appeal in accordance with Article 13.2.3 of the IWF anti-doping rules.
The ITA will not comment further on this case.